CNS infections in patients with hematological or oncological diseases (including cellular therapies) - 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) [0.03%]
德国血液学和肿瘤学协会（DGHO）感染性疾病工作组（AGIHO）关于血液病或肿瘤患者（包括细胞治疗）中枢神经系统感染的2024年指南更新
Rehsan Akdas,Enrico Schalk,Jannik Stemler et al.
Rehsan Akdas et al.
Background: Infections of the central nervous system (CNS) occur in up to 15 % of patients with hematological or oncological diseases (HOD), particularly in high-risk populations. The most common causative agents are viru...
Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment [0.03%]
胰腺导管腺癌一线治疗的真实世界疗效
Mélanie Debiais,Anthony Tarabay,Sarah Blanchet-Deverly et al.
Mélanie Debiais et al.
Background: Metastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis. FOLFIRINOX (FFX) and gemcitabine nab-paclitaxel (GN) are the preferred first line (L1) regimens. We evaluated real-world outcomes of L1 therap...
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) [0.03%]
用于广泛期小细胞肺癌的大规模卡铂、依托泊苷和德瓦鲁单抗一线治疗后的胸部放疗联合维持性德瓦鲁单抗治疗：一项单臂、开放标签的II期临床试验（SAKK 15/19）
Alfredo Addeo,Daniel Dietrich,Nicolas Mach et al.
Alfredo Addeo et al.
Background: Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10-15 % of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC) in the era of checkpoint inhibitors ...
Increased risk of young-onset pancreatic cancer among adults aged 20-39 years with overweight or obesity, but not underweight: A nationwide cohort study [0.03%]
一项全国队列研究：超重或肥胖的20至39岁成人胰腺癌年轻发病风险增加，但体重过轻者没有增加
Hyun-Jin Kim,Joo-Hyun Park,Jung Yong Hong et al.
Hyun-Jin Kim et al.
Background and aims: The incidence of young-onset pancreatic cancer is rapidly increasing worldwide. However, the association between body mass index (BMI), particularly overweight and mild obesity, and the risk of young-...
Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma [0.03%]
PD-1/PD-L1和TIGIT/CD155相互作用的定量空间分析表明胰腺腺鳞癌预后不良和辅助化疗抵抗
Xianlong Chen,Shanyue Sun,Shuofeng Li et al.
Xianlong Chen et al.
Background: Pancreatic adenosquamous carcinoma (PASC) is a rare, highly aggressive pancreatic cancer. Its therapeutic response varies, presumably due to tumor microenvironment (TME) complexity. ...
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study [0.03%]
一项关于携带KRAS G12C突变的非小细胞肺癌患者的Ⅰ/Ⅱ期研究中关于GARSORASIB联合含铂双药化疗治疗的汇总分析
Zhengbo Song,Ziming Li,Yiping Zhang et al.
Zhengbo Song et al.
Introduction: Garsorasib, a KRAS G12C inhibitor, has previously demonstrated its efficacy and safety in patients with KRAS G12C-mutated non-small-cell lung cancer (NSCLC). Here, we present long-term follow-up data from a ...
Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis [0.03%]
基于免疫治疗的胃食管癌临床试验中无进展生存期对总生存期的替代效应：一项荟萃分析
Alberto Giovanni Leone,Fausto Petrelli,Samuel J Klempner et al.
Alberto Giovanni Leone et al.
Background: Immune checkpoint inhibitors (ICIs)-based regimens are the first-line standard of care for most patients with advanced gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC). The e...
Letter re: A deep learning model for preoperative risk stratification of pancreatic ductal adenocarcinoma based on genomic predictors of liver metastasis [0.03%]
关于基于基因组转移预测因子的胰腺导管腺癌术前风险分层的深度学习模型的信件
Xingren Guo,Xiaozheng Li,Xu Wang et al.
Xingren Guo et al.